Design Therapeutics, Inc. financial data

Symbol
DSGN on Nasdaq
Industry
Pharmaceutical Preparations
Location
6005 Hidden Valley Road, Suite 110, Carlsbad, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.81 K % -22.5%
Debt-to-equity 4.51 % +20.3%
Return On Equity -20.8 % -0.29%
Return On Assets -19.9 % +0.45%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 56.5 M shares +0.99%
Common Stock, Shares, Outstanding 56.5 M shares +1.03%
Entity Public Float 164 M USD -56.1%
Common Stock, Value, Issued 6 K USD 0%
Weighted Average Number of Shares Outstanding, Basic 56.5 M shares +1.04%
Weighted Average Number of Shares Outstanding, Diluted 56.5 M shares +1.04%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 51.1 M USD -8.01%
General and Administrative Expense 19.8 M USD -2.39%
Operating Income (Loss) -70.9 M USD +6.5%
Net Income (Loss) Attributable to Parent -58.7 M USD +15.4%
Earnings Per Share, Basic -1.04 USD/shares +16.8%
Earnings Per Share, Diluted -1.04 USD/shares +16.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 29.4 M USD +2.04%
Marketable Securities, Current 241 M USD -15.8%
Cash, Cash Equivalents, and Short-term Investments 271 M USD -14.2%
Other Assets, Current 236 K USD
Assets, Current 274 M USD -14.1%
Property, Plant and Equipment, Net 1.72 M USD -9.82%
Operating Lease, Right-of-Use Asset 2.76 M USD -19.9%
Assets 279 M USD -14.2%
Accounts Payable, Current 1.37 M USD -50%
Employee-related Liabilities, Current 2.07 M USD +15.5%
Accrued Liabilities, Current 5.72 M USD -9.22%
Liabilities, Current 7.09 M USD -21.6%
Operating Lease, Liability, Noncurrent 2.14 M USD -25.6%
Liabilities 9.24 M USD -22.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -167 K USD +91.6%
Retained Earnings (Accumulated Deficit) -189 M USD -45.1%
Stockholders' Equity Attributable to Parent 270 M USD -13.8%
Liabilities and Equity 279 M USD -14.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12.4 M USD +28.6%
Net Cash Provided by (Used in) Financing Activities 724 K USD +208%
Net Cash Provided by (Used in) Investing Activities 20.6 M USD +4.48%
Common Stock, Shares Authorized 200 M shares 0%
Common Stock, Shares, Issued 56.5 M shares +0.98%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 8.2 M USD +255%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 29.4 M USD +2.04%
Deferred Tax Assets, Valuation Allowance 42.4 M USD +58.5%
Deferred Tax Assets, Gross 43.4 M USD +55.3%
Operating Lease, Liability 2.88 M USD -18.6%
Depreciation 143 K USD +10.9%
Payments to Acquire Property, Plant, and Equipment 195 K USD +124%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -56.9 M USD +18.8%
Lessee, Operating Lease, Liability, to be Paid 3.27 M USD -21.5%
Property, Plant and Equipment, Gross 2.92 M USD +14.2%
Operating Lease, Liability, Current 736 K USD +11.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 973 K USD +2.96%
Lessee, Operating Lease, Liability, to be Paid, Year One 945 K USD +2.94%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 393 K USD -37.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 663 K USD -31.9%
Deferred Tax Assets, Operating Loss Carryforwards 15.1 M USD +23.2%
Unrecognized Tax Benefits 1.8 M USD +93.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 663 K USD -31.9%
Deferred Tax Assets, Net of Valuation Allowance 975 K USD -16.5%
Share-based Payment Arrangement, Expense 12.8 M USD +7.13%